Annetine C Gelijns1, Alan J Moskowitz2, Patrick T O'Gara3, Gennaro Giustino2, Michael J Mack4, Donna M Mancini2, Emilia Bagiella2, Judy Hung5, Gorav Ailawadi6, Martin B Leon7, Michael A Acker8, John H Alexander9, Neal W Dickert10, Wendy C Taddei-Peters11, Marissa A Miller11. 1. Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, NY. Electronic address: Annetine.gelijns@mssm.edu. 2. Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, NY. 3. Cardiovascular Division, Brigham and Women's Hospital, Boston, Mass. 4. Cardiothoracic Surgery, Baylor Research Institute, Baylor Scott & White Health, Plano, Tex. 5. Division of Cardiology, Massachusetts General Hospital, Boston, Mass. 6. Section of Adult Cardiac Surgery, University of Virginia, Charlottesville, Va. 7. Center for Interventional Vascular Therapy, Columbia University Medical Center/New York-Presbyterian Hospital and Cardiovascular Research Foundation, New York, NY. 8. Cardiovascular Surgery, Surgery, University of Pennsylvania School of Medicine, Philadelphia, Pa. 9. Division of Cardiology, Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC. 10. Division of Cardiology, Emory University School of Medicine, Atlanta, Ga. 11. Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, Bethesda, Md.
Abstract
OBJECTIVES: Two trials (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation Trial and Percutaneous Repair with the MitraClip Device for Severe Functional/Secondary Mitral Regurgitation Trial) were published in 2018 evaluating the effectiveness and safety of transcatheter repair for patients with heart failure with significant functional mitral regurgitation, which yielded different results. This article reviews the strength of the evidence, differences in trial designs, ethical and implementation implications, and delineates future research needs to help guide the appropriate dissemination of transcatheter repair for functional patients with mitral regurgitation. METHODS: The National Heart, Lung, and Blood Institute convened a workshop of interdisciplinary experts to address these objectives. RESULTS: Transcatheter repair of functional mitral regurgitation can provide significant benefits in terms of heart failure hospitalizations, survival, and quality of life when appropriate heart failure candidates with moderate to severe or severe mitral regurgitation while on optimal guideline-directed medical therapy can be identified. Key ingredients for success are preoperative evaluation and management and postoperative care by an interdisciplinary heart team. CONCLUSIONS: Given the discordance observed between trials, ongoing innovation in patient management, and potential expansion of indications for use, the evidence base must be expanded to optimize appropriate implementation of this complex therapy. This will require more complete capture of outcome data in real-world settings for all eligible candidates whether or not they receive this therapy. Inevitably, the indications for use of this therapy will expand, as will the devices and therapeutic approaches for this population, necessitating the study of comparative effectiveness through randomized trials or observational studies. Moreover, given the substantial variations in care delivery, conducting implementation research to delineate characteristics of the optimal care model would be of benefit.
OBJECTIVES: Two trials (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart FailurePatients with Functional Mitral Regurgitation Trial and Percutaneous Repair with the MitraClip Device for Severe Functional/Secondary Mitral Regurgitation Trial) were published in 2018 evaluating the effectiveness and safety of transcatheter repair for patients with heart failure with significant functional mitral regurgitation, which yielded different results. This article reviews the strength of the evidence, differences in trial designs, ethical and implementation implications, and delineates future research needs to help guide the appropriate dissemination of transcatheter repair for functional patients with mitral regurgitation. METHODS: The National Heart, Lung, and Blood Institute convened a workshop of interdisciplinary experts to address these objectives. RESULTS: Transcatheter repair of functional mitral regurgitation can provide significant benefits in terms of heart failure hospitalizations, survival, and quality of life when appropriate heart failure candidates with moderate to severe or severe mitral regurgitation while on optimal guideline-directed medical therapy can be identified. Key ingredients for success are preoperative evaluation and management and postoperative care by an interdisciplinary heart team. CONCLUSIONS: Given the discordance observed between trials, ongoing innovation in patient management, and potential expansion of indications for use, the evidence base must be expanded to optimize appropriate implementation of this complex therapy. This will require more complete capture of outcome data in real-world settings for all eligible candidates whether or not they receive this therapy. Inevitably, the indications for use of this therapy will expand, as will the devices and therapeutic approaches for this population, necessitating the study of comparative effectiveness through randomized trials or observational studies. Moreover, given the substantial variations in care delivery, conducting implementation research to delineate characteristics of the optimal care model would be of benefit.
Authors: Paul A Grayburn; Blasé Carabello; Judy Hung; Linda D Gillam; David Liang; Michael J Mack; Patrick M McCarthy; D Craig Miller; Alfredo Trento; Robert J Siegel Journal: J Am Coll Cardiol Date: 2014-12-30 Impact factor: 24.094
Authors: William A Zoghbi; David Adams; Robert O Bonow; Maurice Enriquez-Sarano; Elyse Foster; Paul A Grayburn; Rebecca T Hahn; Yuchi Han; Judy Hung; Roberto M Lang; Stephen H Little; Dipan J Shah; Stanton Shernan; Paaladinesh Thavendiranathan; James D Thomas; Neil J Weissman Journal: J Am Soc Echocardiogr Date: 2017-03-14 Impact factor: 5.251
Authors: Suzanne V Arnold; Khaja M Chinnakondepalli; John A Spertus; Elizabeth A Magnuson; Suzanne J Baron; Saibal Kar; D Scott Lim; Jacob M Mishell; William T Abraham; JoAnn A Lindenfeld; Michael J Mack; Gregg W Stone; David J Cohen Journal: J Am Coll Cardiol Date: 2019-03-17 Impact factor: 24.094
Authors: Michael J Mack; William T Abraham; JoAnn Lindenfeld; Steven F Bolling; Ted E Feldman; Paul A Grayburn; Samir R Kapadia; Patrick M McCarthy; D Scott Lim; James E Udelson; Michael R Zile; James S Gammie; A Marc Gillinov; Donald D Glower; David A Heimansohn; Rakesh M Suri; Jeffrey T Ellis; Yu Shu; Saibal Kar; Neil J Weissman; Gregg W Stone Journal: Am Heart J Date: 2018-08-01 Impact factor: 4.749
Authors: Peter K Smith; John D Puskas; Deborah D Ascheim; Pierre Voisine; Annetine C Gelijns; Alan J Moskowitz; Judy W Hung; Michael K Parides; Gorav Ailawadi; Louis P Perrault; Michael A Acker; Michael Argenziano; Vinod Thourani; James S Gammie; Marissa A Miller; Pierre Pagé; Jessica R Overbey; Emilia Bagiella; François Dagenais; Eugene H Blackstone; Irving L Kron; Daniel J Goldstein; Eric A Rose; Ellen G Moquete; Neal Jeffries; Timothy J Gardner; Patrick T O'Gara; John H Alexander; Robert E Michler Journal: N Engl J Med Date: 2014-11-18 Impact factor: 91.245
Authors: Helmut Baumgartner; Volkmar Falk; Jeroen J Bax; Michele De Bonis; Christian Hamm; Per Johan Holm; Bernard Iung; Patrizio Lancellotti; Emmanuel Lansac; Daniel Rodriguez Muñoz; Raphael Rosenhek; Johan Sjögren; Pilar Tornos Mas; Alec Vahanian; Thomas Walther; Olaf Wendler; Stephan Windecker; Jose Luis Zamorano Journal: Eur Heart J Date: 2017-09-21 Impact factor: 29.983
Authors: Adnan K Chhatriwalla; Sreekanth Vemulapalli; David R Holmes; Dadi Dai; Zhuokai Li; Gorav Ailawadi; Donald Glower; Saibal Kar; Michael J Mack; Jennifer Rymer; Andrzej S Kosinski; Paul Sorajja Journal: JACC Cardiovasc Interv Date: 2019-07-22 Impact factor: 11.195
Authors: Gregg W Stone; JoAnn Lindenfeld; William T Abraham; Saibal Kar; D Scott Lim; Jacob M Mishell; Brian Whisenant; Paul A Grayburn; Michael Rinaldi; Samir R Kapadia; Vivek Rajagopal; Ian J Sarembock; Andreas Brieke; Steven O Marx; David J Cohen; Neil J Weissman; Michael J Mack Journal: N Engl J Med Date: 2018-09-23 Impact factor: 91.245